“Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis” - Kither Biotech

Skip to content

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

×

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Campa et al (& Sala, Hirsch), Nature Communications.

Research Article

Recent articles

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases
Kither Biotech and Pantherna Therapeutics Announce Strategic Collaboration on Synergistic mRNA and Peptide Therapies for Genetic Lung Diseases
Kither Biotech Announces Phase 1 Clinical Study Of KIT2014, A Novel Inhaled Peptide Therapy For Cystic Fibrosis
Kither Biotech Announces Appointment of Dr. Dimitrios Goundis to Board of Directors
Kither Biotech announces publication of new data in Science Translational Medicine

Dynamic scientific development for a better tomorrow

Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.

Linkedin Youtube

Menu

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

×

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Contact

Via Nizza 52, 10126,
Turin (TO), Italy
info@kitherbiotech.com

Useful information

Privacy Policy
Cookie Policy

KITHER BIOTECH S.R.L. © COPYRIGHT 2021-2025. P. IVA 10615040010. DESIGN BY WEB AGENCY TORINO – WEB BRAND